AbbVie
AbbVie (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and sells medicines and therapies for complex diseases. Its portfolio spans immunology, neuroscience, oncology, aesthetics, eye care and other therapeutic areas, with products including Skyrizi, Rinvoq,… From the company’s description.
In fiscal 2025, AbbVie reported revenue of $61.16B, up 8.6% from fiscal 2024, and net income of $4.23B. Its operating margin was 24.6%, and operations generated $19.03B in cash. Over the twelve months to Jun 30, 2026, revenue was $64.39B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AbbVie does
In the company’s own words
AbbVie (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and sells medicines and therapies for complex diseases. Its portfolio spans immunology, neuroscience, oncology, aesthetics, eye care and other therapeutic areas, with products including Skyrizi, Rinvoq, Humira, Botox, Vraylar, Imbruvica, Venclexta and Juvederm. AbbVie operates as a single global business segment, combining research and development, manufacturing, commercialization and sales; commercial activities are coordinated by geography or therapeutic area. Its customers include wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, independent retailers, physicians and other licensed health care providers, as well as managed care organizations and hospitals. The company markets to health care professionals and payers and also conducts direct-to-consumer marketing. AbbVie became an independent, publicly traded company in 2013 through the distribution of its common stock to Abbott Laboratories shareholders.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NORTH CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1551152
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AbbVie — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in AbbVie · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · AbbVie’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
AbbVie’s bonds, as funds hold them
Funds report holding 39 issues of AbbVie’s debt, $10.56B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.47%, maturing 2026 to 2066.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AbbVie and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AbbVie's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AbbVie's last four quarterly filings that the numbers alone won't show?”